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21 Introduction 
The Swiss Childhood Cancer Registry is the national cancer registry for children in Switzerland. It is a 
population-based registry with integrated clinical data. In February 2005, the SCCR became an 
associate member of the International Association of Cancer Registries (IACR) and the European 
Network of Cancer Registries (ENCR). Since 1976, all Swiss hospitals treating paediatric cancer 
patients (9 hospitals) report newly diagnosed children to the registry. With the long-term follow up of 
these children, survival, late effects and secondary tumours are being studied. Data are collected by 
all clinicians caring for children with cancer in Switzerland, who are organised in the Swiss Paediatric 
Oncology Group (SPOG; clinics in Aarau, Basel, Bern, Geneva, Lausanne, Lucerne, St. Gallen, 
Locarno, Zurich). 
The SCCR collaborates with the Association of Swiss Cancer Registries (VSKR), the German 
Childhood Cancer Registry (GCCR), the National Registry of Childhood Tumours in the UK in Oxford 
(NRCT) and other national childhood cancer registries. 
In this second Annual Report we present a description of the organisation and staff of the SCCR at the 
Institute of Social and Preventive Medicine (University of Bern) and the participating paediatric 
haematology-oncology clinics of the SPOG (chapter 2), and we present a summary of the data 
collected in the registry (chapter 3). Chapter 4 describes the research projects of the SCCR, together 
with an overview of the nested projects, for which the SCCR extracted datasets or provided analyses. 
A review of the activities of the SCCR in 2005 and 2006 can be found in chapter 5. To conclude this 
annual report, a list of the latest publications is given in chapter 6. 
A detailed description of the history of the SCCR can be found in the annual report 2004 (download at: 
www.kinderkrebsregister.ch). 
We would like to thank the SPOG clinicians and datamanagers for all their work for the SCCR, and the 
firms who are generously supporting the work of the SCCR. 
 
32 Organisation of the Swiss Childhood Cancer Registry 
2.1 Staff 
The Swiss Childhood Cancer Registry (SCCR) is run jointly by the Swiss Paediatric Oncology Group 
(SPOG) and the Institute of Social and Preventive Medicine (ISPM) at the University of Bern. 
 
2.1.1 Institute of Social and Preventive Medicine (ISPM), University of Bern 
Finkenhubelweg 11, 3012 Bern, 
Tel: +41 (0)31 631 38 99, Fax: +41 (0)31 631 35 20, 
e-mail: kinderkrebsregister@ispm.unibe.ch 
Management of the SCCR 
Dr. med. Claudia Kuehni 
FMH (Paediatrics), MSc (Epidemiology) 
Overall responsibility kuehni@ispm.unibe.ch 
Dr. phil. Gisela Michel, PhD Project Management michel@ispm.unibe.ch 
Scientific Staff 
Dr. med. Elisabeth Kiraly  Diagnostic Coding kiraly@ispm.unibe.ch 
Marie-Pierre Strippoli MSc (Med Stats) Statistics strippol@ispm.unibe.ch 
Martin Adam, Sc.nat. ETH Research project: 
Completeness of cancer 
registration and diagnostic 
accuracy in the SCCR 
madam@ispm.unibe.ch 
Cornelia E. Rebholz, Sc.nat. ETH Research project: 
Long-term outcome of childhood 
cancer: incidence and spectrum 
of late effects 
crebholz@ispm.unibe.ch 
Administration and Computer Science 
Malcolm Sturdy  Computer Science sturdy@ispm.unibe.ch 
2.1.2 Swiss Paediatric Oncology Group (SPOG) 
SIAK Koordinationszentrum, Effingerstrasse 40, 3008 Bern, 
Fax: +41 (0)31 389 92 00 
SPOG Executive 
PD Dr. med. Nicolas von der Weid President Nicolas.Von-Der-Weid@chuv.ch 
Prof. Dr. med. Felix Niggli Vice President felix.niggli@kispi.unizh.ch 
Dr. med. Heinz Hengartner Secretary heinz.hengartner@kispsisg.ch 
Central Office in Bern 
Liselotte Lang (until March 2007) Central administration liselotte.lang@siak.ch 
Barbara Kindler (since April 2007) Central administration barbara.kindler@sakk.ch 
Friedgard Julmy Clinical trials, ethic committee 
submissions 
friedgard.julmy@insel.ch 
4Participating Clinics (Haemato-oncology) Head of Division Local Data-Manager 
Aarau (Kinderklinik Kantonsspital Aarau): Dr. med. R. Angst Dr. med. R. Angst 
Basel (Universitätskinderspital beider Basel): Prof. Dr. med. M. Paulussen V. Stahel 
Bern (Universitäts-Kinderklinik Inselspital): Prof. Dr. med. A. Hirt K. Zimmermann 
Geneva (Hôpital des Enfants): PD Dr. med. A.H. Ozsahin M. Berner 
Lausanne (Service de Pédiatrie CHUV): Dr. med. M. Beck-Popovic 
PD Dr. med. N. von der Weid 
Dr. med. R. M. Garcia 
Locarno (Reparto di Pediatria, Ospedale 
Regionale di Locarno): 
Dr. med. L. Nobile Dr. med. L. Nobile 
Lucerne (Kantonspital Luzern, Kinderspital): Dr. med. U. Caflisch S. Ettlin 
St. Gallen (Ostschweiz. Kinderspital): Dr. med. J. Greiner R. Fussenegger 
Zurich (Universitäts-Kinderklinik Zürich): Prof. Dr. med. F. Niggli H. Markievicz 
2.2 General information 
The SCCR is an associate member of the International Association of Cancer Registries (IACR) and 
the European Network of Cancer Registries (ENCR). 
2.2.1 Inclusion criteria and data collection 
The SCCR includes the following diagnoses: i) Acute and chronic leukaemias, including 
myelodysplastic syndrome, ii) All solid malignancies, iii) All central nervous system tumours (CNS), 
including benign tumours, iv) Langerhans cell histiocytocis and other histiocytoses (type I–III). We aim 
for complete registration of all children below the age of 16 years who are diagnosed with cancer at 
one of the nine Swiss clinics for paediatric oncology and haematology. Occasionally older patients 
who are suffering from a paediatric cancer and are treated at these 9 clinics are also registered but 
unsystematically, as are children who are not residents of Switzerland but come here for treatment 
(these patients are not included in the analyses of incidence). Follow-up data is extracted once or 
twice a year from the patients’ hospital records for the first 5 years after diagnosis. Thereafter follow-
up data are obtained from the patients’ general practitioners or paediatricians. In each of the nine 
centres a local data manager completes the data forms. These are sent to the central office of the 
SPOG; forwarded to the SCCR and entered into the database. Paper copies are stored at the SPOG 
central administration.  
2.2.2 Current database 
The electronic database of the SCCR which is currently in use has been developed by PD Dr. Nicolas 
von der Weid in 1992. At present, the database contains the following information on cancer patients: 
• Patient’s name, current address, and phone number, and address at the time of diagnosis. 
• Name and address of the general practitioner or paediatrician and the paediatric oncology 
clinic treating the child. 
• Demographic information (date of birth, gender) 
• Socio-economic information (parental profession, place of origin, country of residence) 
• Tumour diagnosis, date of diagnosis, type of cancer, histology, stage, metastases 
• Other diagnoses, relevant pre-existing disease conditions 
• Clinical information and laboratory values 
5• Treatment (treatment protocols, medication and dosages, radiotherapy, surgical interventions, 
others) 
• Follow-up data concerning change of treatment, remission, relapses, survival/death and cause 
of death 
• Late effects due to malignancy and therapy 
A new electronic database is currently being programmed and will commence operation in July 2007. 
A detailed description will be available in the next annual report. 
2.2.3 Tumour coding 
Until 2004, all tumours were coded according to the coding used by the American Paediatric Oncology 
Group (POG). In addition, the exact diagnosis including details on location and staging was recorded. 
In 2004 the SCCR started to code new tumours according to the following international classifications 
(see Appendix 1):  
1. The third edition of the International Classification of Childhood Cancer (ICCC-3)1
2. The third edition of the International Classification of Diseases for Oncology (ICD-O-3)2
3. The tenth edition of the International Statistical Classification of Diseases and Related Health 
Problems (ICD-10)3.
In 2006, all tumours contained in the database were double-coded by two physicians according to the 
three classification systems shown above.  
To present data in the annual report the following classification for general diagnostic groups – a 
summary from the ICCC-3 classification – has been used: I. Leukaemias, II. Lymphomas, III. CNS 
tumours, IV. Sympathetic Nervous System (SNS) tumours, V. Retinoblastoma, VI. Renal tumours, VII. 
Hepatic tumours, VIII. Bone tumours, IX. Soft Tissue Sarcomas (STS) X. Germ cell tumours, XI. 
Carcinomas, XII. Other neoplasms. In addition, Langerhans cell histiocytoses are reported. 
 
1 Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer 
2005;103(7):1457-67. 
2 World Health Organization. International Statistical Classification of Diseases for Oncology - 3rd Edition (ICD-O-3). Geneva: 
World Health Organization; 2000. 
3 World Health Organization. International statistical classification of diseases and related health problems - Tenth Edition. 
Geneva: World Health Organization; 1993. 
63 Routine analyses 
Up to December 31 2005 a total of 5014 tumour cases have been registered (4406 being Swiss 
residents). Known Swiss residents accounted for 87.9 % of all patients, and foreign residents treated 
in Switzerland for 9.6% (see Table 1). For retinoblastoma 52.8% (134/254) of cases were foreign 
residents. This is mainly due to the Jules Gonin Eye Hospital at the University Hospital in Lausanne, 
which has treated 170 of the total 254 cases of retinoblastoma. 
When comparing the results of this year’s analyses to the ones published in the previous annual 
report, there are some small differences in the numbers. Because the SCCR is a dynamic registry this 
is to be expected and is caused by occasional later additions and corrections of cases. In addition, all 
tumours were retrospectively classified according to ICCC-3, which might have caused a small 
modification in the exact diagnostic code (see 2.2.3 Tumour coding). 
Systematic registration of all patients participating in clinical trials started in 1976 and the number of 
patients registered per year increased considerably after non-trial patients were included in 1981. After 
1994 annual registration increased only very slightly. Between 2001 and 2005, there were about 217 
new cases each year (about 203 of them Swiss residents (including Langerhans cell histiocytosis, 
LCH); Figure 1 and Table 2). 
For the remaining analyses only Swiss residents aged under 15 years with a diagnosis according to 
ICCC-3 or LCH are included. 
1006 patients were reported to have died and 681 patients are lost to follow-up. For 1434 patients 
(34.8%) the latest follow-up information was reported after 31 December 2002 and for 141 patients the 
latest information comes from the time between 2000 and 2002 (see Table 3).  
Nearly half of the cases (47%) have been diagnosed at age 4 years or less, 10.4 % at less than 1 year 
of age and 36.6% between 1-4 years of age (Table 4 and Figure 2). The number of cases per age 
group declined from infancy to age 8 years and began to increase again until age 13 (Figure 3 and 
Figure 4).  
One third of childhood cancers diagnosed in Swiss children between 1996 and 2005 were leukaemias 
(32.5%), followed by tumours of the central nervous system (CNS-tumours, 23.0%) and lymphomas 
(12.2%). Details of each diagnostic code (ICCC-3) for all Swiss patients diagnosed until 31 Dec 2005 
are shown in Table 5 and Figure 5; details of the diagnosis for Swiss patients aged under 15 years 
and diagnosed in the last 10 years (between 1996 and 2005) are given in Table 6.  
As found in other childhood cancer registries there was a higher number of boys than girls. This was 
true for most types of tumours with the exception of neuroblastomas, germ cell neoplasms and other 
malignant and epithelial tumours (Table 6). 
The distribution of patients among the 9 SPOG clinics is shown in Table 7, Table 8, and Table 9. In 
2005 most patients were treated in Zurich, followed by Lausanne and Bern. 
The age-standardized incidence of any childhood cancer (not including LCH) in the past 5 years was 
15.7 cases per 100’000 person/years in Switzerland (age-standardization according to the world 
population for the age-groups under 15 years4). Age adjusted incidence was highest among children 
aged less than 1 year with 28.0 cases per 100’000 and lowest in 9 year olds with 9.0 cases per 
100’000 (Figure 6 shows the crude incidence rates and Figure 7 shows age- and gender-specific 
incidence rates).  
 
4 Parkin DM, Kramarova E, Draper GJ, Masuyer E, Michaelis J, Neglia J, et al. The international incidence of childhood cancer, 
Vol II. Lyon: IARC Scientific Publications; 1998. 
7Table 1 Registered cases in the SCCR according to country of residence 
Country of residence Number of cases % of total cases
1 Switzerland 4406 87.9 
2 Other countries 481 9.6 
 a Europe 335 6.7 
 Neighbouring countries* 207 4.1 
 Other European countries 128 2.6 
 b Middle East 10 0.2 
 c North Africa 77 1.5 
 d Other African countries 35 0.7 
 e Other countries 21 0.4 
3 Country of residence missing 127 2.5 
 Before 1990 120 94.5 
 After 1990 7 5.5 
Total Cases  5014 100 
* Austria (N=7), France (N=51), Germany (N=43), Italy (N=97), Lichtenstein (N=9) 
 
Table 2 Number of new cases registered in the SCCR, for 5-year intervals 
Year of Diagnosis All patients Swiss residents 
until 1980 485 418 
1981-1985 658 565 
1986-1990 779 631 
1991-1995 982 856 
1996-2000 1022 919 
2001-2005 1088 1017 
8Figure 1 Number of new patients registered each year in the SCCR 
 
Table 3 Number of patients in the SCCR database (Swiss residents aged under 15 years) 
 Number of patients % 
Died 1006 24.4 
Last follow-up after 31 Dec 2002 1434 34.8 
Last follow-up 2000-2002 141 3.4 
Last follow-up before 1 Jan 2000 509 12.3 
Lost to follow-up 681 16.5 
no Information 351 8.5 
Total until December 31 2005 4122 100.0 
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9Table 4  Age at diagnosis (Swiss residents aged under 15 years) 
Age in years 
 Number of 
patients % 
< 1 430 10.4 
1 – 4 1508 36.6 
5 – 9 1113 27.0 
10 – 14  1071 26.0 
Total <15 years 4122 100.0
Figure 2 Age at diagnosis (Swiss residents aged under 15 years diagnosed between 1 Jan 1976 and 31 Dec 
2005) 
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Figure 3 Age at diagnosis (Swiss residents aged under 15 years, N=4122) 
 
Figure 4 Age at diagnosis, by sex (Swiss residents aged under 15 years, N=4122) 
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Table 5 Details on diagnostic group according to ICCC-3 (Swiss residents aged under 15 years diagnosed 
between 1 Jan 1976 and 31 Dec 2005) 
 Total Age group 
Diagnosis number <1yr 1-4yrs 5-9yrs 10-14yrs
I Leukaemias 1461 52 705 417 287 
II Lymphomas 561 16 87 163 295 
III CNS neoplasms 708 55 215 262 176 
IV Neuroblastoma  275 123 117 23 12 
V Retinoblastoma 113 54 49 8 2 
VI Renal tumours 234 36 137 53 8 
VII Hepatic tumours 40 11 15 5 9 
VIII Malignant bone 
tumours 172 0 14 53 105 
IX Soft tissue sarcomas 245 29 75 67 74 
X Germ cell tumours 103 18 25 14 46 
XI Carcinomas 46 3 5 8 30 
XII Other and 
unspecified malignant 
neoplasms 6 0 3 1 2 
 Langerhans Cell 
Histiocytosis 158 33 61 39 25 
 Total 4122 430 1508 1113 1071 
Figure 5 Distribution of diagnoses according to ICCC-3 (Swiss residents aged under 15 years diagnosed 
between 1 Jan 1976 and 31 Dec 2005) 
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Table 6 Diagnosis according to ICCC-3 in Swiss patients aged under 15 years diagnosed between 1996 and 
2005 
Number Relative
Frequency
Sex Ratio 
(male: female)
Mean
age 
Incidence 
(per 1Mio)
I Leukaemias, myeloproliferative diseases, and myelodysplastic 
diseases 
562 32.5 1.4 4.8 45.7 
a. Lymphoid leukaemias 448 79.7 1.4 4.7 36.4 
 b. Acute myeloid leukaemias 83 14.8 1.2 5.4 6.7 
 c. Chronic myeloproliferative diseases 5 0.9 1.5 9.5 0.4 
 d. Myelodysplastic syndrome and other myeloproliferative diseases 18 3.2 1.0 8.5 1.5 
 e. Unspecified and other specified leukaemias 8 1.4 3.0 5.3 0.7 
II Lymphomas and reticuloendothelial neoplasms 211 12.2 1.8 10.6 17.2 
 a. Hodgkin lymphomas 80 37.9 1.3 12.8 6.5 
 b. Non-Hodgkin lymphomas (except Burkitt) 101 47.9 2.1 9.0 8.2 
 c. Burkitt lymphoma 25 11.8 4.0 8.5 2.0 
 d. Miscellaneous lymphoreticular neoplasms 4 1.9 3.0 0.9 0.3 
 e. Unspecified lymphomas 1 0.5 0.0 13.6 0.1 
III CNS and miscellaneous intracranial and intraspinal neoplasms 397 23.0 1.2 6.3 32.3 
 a. Ependymomas and choroid plexus tumours 40 10.1 1.4 2.1 3.3 
 b. Astrocytomas 146 36.8 1.2 6.6 11.9 
 c. Intracranial and intraspinal embryonal tumours 105 26.4 1.9 5.8 8.5 
 d. Other gliomas 41 10.3 0.8 6.4 3.3 
 e. Other specified intracranial and intraspinal neoplasms 61 15.4 0.8 10.1 5.0 
 f. Unspecified intracranial and intraspinal tumours 4 1.0 1.0 11.9 0.3 
V Neuroblastomas and other peripheral nervous cell tumours 101 5.8 0.9 1.0 8.2 
 a. Neuroblastoma and ganglioneuroblastoma 101 100.0 0.9 1.0 8.2 
V Retinoblastomas 51 2.9 1.0 0.8 4.1 
VI Renal Tumours: Nephroblastoma and other nonepithelial tumours 96 5.6 1.0 3.3 7.8 
 a. Nephroblastoma and other nonepithelial renal tumours 95 99.0 1.1 3.2 7.7 
 b. Renal carcinomas 1 1.0 0.0 14.7 0.1 
VII Hepatic tumours 27 1.6 3.5 1.6 2.2 
 a. Hepatoblastomas 20 74.1 5.7 1.2 1.6 
 b. Hepatic carcinomas 7 25.9 1.3 13.4 0.6 
VIII Malignant bone tumours 90 5.0 1.0 11.0 7.3 
 a. Osteosarcomas 47 52.2 0.7 10.8 3.8 
 c. Ewing tumour and related sarcomas of bone 43 47.8 1.3 11.0 3.5 
IX Soft tissue and other extraosseous sarcomas 115 6.7 1.4 6.6 9.3 
 a. Rhabdomyosarcomas 73 63.5 2.0 5.0 5.9 
 b. Fibrosarcomas, peripheral nerve sheath tumours and other fibrous 
neoplasms 
9 7.8 2.0 1.1 0.7 
 d. Other specified soft tissue sarcomas 21 18.3 0.8 11.3 1.7 
 e. Unspecified soft tissue sarcomas 12 10.4 0.3 9.7 1.0 
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 50 2.9 0.8 8.2 4.1 
 a. Intracranial and intraspinal germ cell tumours 14 28.0 2.5 10.9 1.1 
 b. Malignant extracranial and extragonadal tumours 12 24.0 0.2 1.3 1.0 
 c. Malignant gonadal germ cell tumours 23 46.0 0.8 10.1 1.9 
 d. Gonadal carcinomas 1 2.0 0.0 13.9 0.1 
XI Other malignant epithelial neoplasms and malignant melanomas 28 1.6 0.9 11.7 2.3 
 a. Adrenocortical carcinomas 4 14.3 0.3 8.4 0.3 
 b. Thyroid carcinomas 13 46.4 0.9 12.7 1.1 
 d. Malignant melanomas 6 21.4 1.0 11.5 0.5 
 e. Skin carcinomas 1 3.6  2.6 0.1 
 f. Other and unspecified carcinomas 4 14.3 1.0 11.0 0.3 
XII Other and unspecified malignant neoplasms 1 0.1  12.9 0.1 
 b. Other unspecified malignant tumours 1 100.0  12.9 0.1 
 Total (not including Langerhans Cell Histiocytosis) 1729 100.0 1.3 6.0 140.5 
Langerhans Cell Histiocytosis 63 3.5 1.5 3.7 5.1 
Total (including Langerhans Cell Histiocytosis) 1792 100.0 1.3 6.4 145.7 
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Table 7 Diagnosed childhood cancer cases*, by participating paediatric oncology clinic (total database 1976-1995**)
Diagnosis Total % Aarau % Basel % Bern % Geneva % Lausanne % Locarno % Lucerne % St. Gallen % Zurich % Other %
I Leukaemias 1022 100 72 7.0 102 10.0 281 27.5 88 8.6 98 9.6 16 1.6 79 7.7 107 10.5 176 17.2 3 0.3
II Lymphomas 424 100 29 6.8 44 10.4 103 24.3 37 8.7 61 14.4 7 1.7 25 5.9 37 8.7 80 18.9 1 0.2
III CNS neoplasms 395 100 25 6.3 31 7.8 147 37.2 29 7.3 49 12.4 8 2.0 8 2.0 34 8.6 64 16.2 0 0.0
IV Neuroblastoma 211 100 7 3.3 20 9.5 40 19.0 21 10.0 38 18.0 0 0.0 15 7.1 18 8.5 51 24.2 1 0.5
V Retinoblastoma*** 141 100 0 0.0 6 4.3 16 11.3 15 10.6 81 57.4 2 1.4 6 4.3 8 5.7 7 5.0 0 0.0
VI Renal tumours 159 100 5 3.1 14 8.8 36 22.6 10 6.3 20 12.6 0 0.0 17 10.7 15 9.4 41 25.8 1 0.6
VII Hepatic tumours 19 100 0 0.0 1 5.3 9 47.4 2 10.5 2 10.5 0 0.0 0 0.0 0 0.0 5 26.3 0 0.0
VIIIMalignant bone tumours 154 100 5 3.2 23 14.9 47 30.5 19 12.3 29 18.8 2 1.3 6 3.9 10 6.5 12 7.8 1 0.6
IX Soft tissue sarcomas 169 100 6 3.6 16 9.5 45 26.6 11 6.5 29 17.2 3 1.8 13 7.7 19 11.2 27 16.0 0 0.0
X Germ cell tumours 78 100 6 7.7 7 9.0 18 23.1 7 9.0 12 15.4 2 2.6 2 2.6 4 5.1 20 25.6 0 0.0
XI Carcinomas 24 100 1 4.2 1 4.2 6 25.0 4 16.7 6 25.0 1 4.2 1 4.2 1 4.2 3 12.5 0 0.0
XII Other and unspecified malignant
neoplasms
7 100 0 0.0 1 14.3 2 28.6 0 0.0 3 42.9 0 0.0 0 0.0 0 0.0 1 14.3 0 0.0
Langerhans Cell Histiocytosis 101 100 4 4.0 14 13.9 24 23.8 4 4.0 11 10.9 1 1.0 6 5.9 19 18.8 18 17.8 0 0.0
Total 2904 100 160 5.5 280 9.6 774 26.7 247 8.5 439 15.1 42 1.4 178 6.1 272 9.4 505 17.4 7 0.2
* Diagnosis coded according to the ICCC-3
** All patients irrespective of age and residency (Swiss and foreign patients) are included in this analysis
*** Most cases with retinoblastoma are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne
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Table 8 Diagnosed childhood cancer cases*, by participating paediatric oncology clinic (patients diagnosed between 1996 and 2005**)
Diagnosis Total % Aarau % Basel % Bern % Geneva % Lausanne % Locarno % Lucerne % St. Gallen % Zurich % Other %
I Leukaemias 633 100 44 7.0 52 8.2 109 17.2 49 7.7 90 14.2 17 2.7 45 7.1 64 10.1 163 25.8 0 0.0
II Lymphomas 264 100 16 6.1 16 6.1 49 18.6 21 8.0 44 16.7 9 3.4 29 11.0 23 8.7 57 21.6 0 0.0
III CNS neoplasms 437 100 23 5.3 26 5.9 98 22.4 45 10.3 72 16.5 14 3.2 4 0.9 37 8.5 118 27.0 0 0.0
IV Neuroblastoma 112 100 4 3.6 13 11.6 16 14.3 9 8.0 20 17.9 1 0.9 9 8.0 9 8.0 31 27.7 0 0.0
V Retinoblastoma*** 113 100 0 0.0 5 4.4 4 3.5 3 2.7 88 78.8 1 0.0 3 2.7 3 2.7 6 5.3 0 0.0
VI Renal tumours 104 100 7 6.7 11 10.6 19 18.3 14 13.5 13 12.5 4 3.8 5 4.8 9 8.7 22 21.2 0 0.0
VII Hepatic tumours 30 100 4 13.3 3 10.0 4 13.3 1 3.3 5 16.7 2 6.7 0 0.0 4 13.3 7 23.3 0 0.0
VIIIMalignant bone tumours 125 100 6 4.8 24 19.2 22 17.6 17 13.6 21 16.8 2 1.6 3 2.4 10 8.0 20 16.0 0 0.0
IX Soft tissue sarcomas 130 100 12 9.2 12 9.2 20 15.4 9 6.9 22 16.9 1 0.8 13 10.0 10 7.7 31 23.8 0 0.0
X Germ cell tumours 59 100 7 11.9 2 3.4 9 15.3 7 11.9 11 18.6 1 1.7 5 8.5 5 8.5 11 18.6 1 1.7
XI Carcinomas 35 100 3 8.6 5 14.3 8 22.9 2 5.7 3 8.6 1 2.9 3 8.6 4 11.4 6 17.1 0 0.0
XII Other and unspecified malignant
neoplasms
1 100 0 0.0 0 0.0 0 0.0 1 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Langerhans Cell Histiocytosis 65 100 5 7.7 4 6.2 17 26.2 2 3.1 12 18.5 3 4.6 4 6.2 5 7.7 13 20.0 0 0.0
Total 2108 100 131 6.2 173 8.2 375 17.8 180 8.5 401 19.1 56 2.6 123 5.8 183 8.7 485 23.0 1 0.0
* Diagnosis coded according to the ICCC-3
** All patients irrespective of age and residency (Swiss and foreign patients) are included in this analysis
*** Most cases with retinoblastoma are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne
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Table 9 Diagnosed childhood cancer cases*, by participating paediatric oncology clinic (new patients diagnosed in 2005**)
Diagnosis Total Aarau Basel Bern Geneva Lausanne Locarno Lucerne St. Gallen Zurich
I Leukaemias 70 4 5 10 6 8 1 7 8 21
II Lymphomas 34 1 3 7 2 5 0 3 6 7
III CNS neoplasms 55 1 2 10 2 8 1 1 3 27
IV Neuroblastoma 7 0 0 1 0 1 0 3 0 2
V Retinoblastoma*** 14 0 0 1 0 10 1 1 1 0
VI Renal tumours 11 2 0 1 1 2 0 0 2 3
VII Hepatic tumours
VIIIMalignant bone tumours 15 0 8 0 0 4 0 0 0 3
IX Soft tissue sarcomas 15 2 5 2 1 0 0 0 1 4
X Germ cell tumours 3 0 0 0 0 1 0 2 0 0
XI Carcinomas 3 0 0 0 0 0 0 1 0 2
XII Other and unspecified malignant neoplasms
Langerhans Cell Histiocytosis 6 1 0 2 0 1 0 1 0 1
Total 233 11 23 34 12 40 3 19 21 70
* Diagnosis coded according to the ICCC-3
** All patients irrespective of age and residency (Swiss and foreign patients) are included in this analysis
*** Most cases with retinoblastoma are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne
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Figure 6 Crude incidence rates in Switzerland for all malignancies between 1990 and 2005 for children aged  
0-14 years (not including Langerhans cell histiocytosis) 
 
Figure 7 Age- and sex-specific incidence rates (Switzerland 2001-2005, not including Langerhans cell 
histiocytosis) 
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4 Current research projects at the SCCR 
4.1 Collaboration with SPOG studies (data-extraction or analysis) 
We extracted data or performed analyses for studies conducted by different SPOG clinics.  
1. Title:  Survival of childhood cancer in the past 30 years in Zurich 
Applicant:  Prof. Dr. med. F. Niggli 
Population: 655 children with cancer treated in Zurich for whom follow-up information is available. 
167 of these patients were registered as having died 
 
2. Title:  Retinoblastoma treatment in Switzerland 
Supervisor  Dr. med. F. M. Beck Popovic 
Student:  M. Wallach 
Population: In August 2005, there were 245 patients with retinoblastomas registered in the SCCR. 
161 of these patients were treated in Lausanne and 84 in other clinics 
Data extracted: Year of diagnosis, treating institutions 
Publications:  Wallach, M., Balmer, A., Munier, F., Houghton, S., Pampallona, S., von der Weid, N., 
et al. (2006). Shorter time to diagnosis and improved stage at presentation in Swiss 
patients with retinoblastoma treated from 1963 to 2004. Pediatrics, 118(5), e1493-
1498. DOI:10.1542/peds.2006-0784 
 
3. Title:  Renal tumours in Switzerland 
Supervisor  Dr. med. M. Diezi 
Extraction: From 1992 to 2004, the SCCR registered 145 patients with renal tumours. 8 of these 
patients are not Swiss residents but only came here for treatment. The average 
annual number of new cases was 11.2 from 1992 to 2004. The mean age of the 
children at diagnoses was 3.5. 
Publications:  Diezi M, Tercier S, Osterheld M-C, Joseph J-M, Tumeurs rénales de l’enfant. Revue 
Médicale Suisse 2007;3:360-5 
 
4. Title:  Childhood acute myeloid leukaemia: the clinical significance of cytogenetic events at 
presentation and relapse 
Supervisor  Dr. D. Betts 
Population: For 99 of the 103 patients tumour and therapy details were extracted from the SCCR. 
Data extracted: Date of 1st Diagnosis, Date 2nd Diagnosis, Date 3rd Diagnosis, Date 1st relapse, Date 
2nd relapse, Date 3rd relapse, Date last seen, Date lost to follow-up, Date exitus, Bone 
marrow transplantation (1 yes/0 no), Date bone marrow transplantation, bone marrow 
transplantation type, code bone marrow transplantation, prior Disease (1 yes/ 0 no), 
description of prior disease, survival time, event-free survival time  
Publications:  under review 
 
5. Title:  Wilm’s Tumour, Soft Tissue Sarcoma and autologous bone marrow transplantation 
Supervisor  PD Dr. med. N. von der Weid 
Population: For the years 2000 to 2005, data on 3 patients with either Wilm’s Tumour or Soft 
Tissue Sarcoma and an autologous bone marrow transplantation were extracted 
Data extracted: Diagnosis, year of diagnosis, autologous bone marrow transplantation 
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6. Title:  Number of patients with Ewing-Sarcomas or Rhabdomyosarcomas 
Supervisor  Prof. Dr. med. M. Paulussen 
Population: For the years 2000 to 2004, 32 patients with Rhabdomyosarcoma, 23 with Ewing-
Sarcomas, 7 with extra-osseus Ewing-Sarcomas and 3 with a rhabdoid malignancy 
were extracted. 
Data extracted: Diagnosis, year of diagnosis 
 
7. Title:  Leukaemia in Switzerland 
Supervisor  Dr. J.-P. Bourquin 
Population: Leukaemia cases in Switzerland since 1994 by sex. 
Data extracted: Diagnosis, year of diagnosis, gender 
 
8. Title:  Craniopharyngeoma patients in Bern 
Supervisor  Dr. M. Janner 
Population: all patients diagnosed with a craniopharyngeoma in Bern (N=17) 
Data extracted: First name, family name, date of birth, date of diagnosis, gender 
 
4.2 SCCR research projects 
In 2005 and 2006, four research projects started as nested studies of the SCCR. 
4.2.1 Long-term outcome of childhood cancer: incidence and spectrum of late effects  
Aims: The Swiss Childhood Cancer Survivor Study of the SCCR aims to investigate the long-term 
outcome of former childhood cancer patients who were diagnosed with cancer before the age of 16 
years and who survived for more than 5 years. The project aims to assess the incidence of various 
somatic outcomes (late mortality, secondary malignancies, endocrine disorders, infertility, 
cardiovascular events), and their association with a number of risk factors assessed prospectively at 
the time of diagnosis (tumour, treatment modalities, demographic characteristics). In addition, the 
current practice of health-care provision and health behaviour in long-term survivors will be 
investigated. 
Study progress: In 2006, the questionnaire for the study was developed and 100 survivors from Bern 
and Zurich (50 from each clinic) were contacted by means of a letter from their former clinic and 
invited to participate in the study. None of the survivors who received the letter declined to participate 
in the study. They received the questionnaire 3 weeks after the first contact. 
By the end of 2007 all survivors should have received the questionnaire. Separate questionnaires are 
used for adults older than 20 years, adolescents older than 14 years and children (parents are asked 
to fill in the questionnaire and only a short questionnaire assessing quality of life is filled in by the 
children themselves). Questionnaires are available in German and French. 
Collaborators: The research proposal is a collaborative project of the SPOG (PD Dr. Nicolas von der 
Weid, Main Investigator), the ISPM Bern (Prof. Dr. Matthias Egger, Dr. Claudia Kuehni, Co-applicants) 
and the cantonal registries (PD Dr. Nicole Probst-Hensch, Co-applicant). 
Members of the late effects study group: 
Dr. med. Claudia Kuehni, Dr. phil. Gisela Michel, PD Dr. med. Nicolas von der Weid, Dr. phil. Marcel 
Zwahlen, Prof. Dr. med. Felix Niggli, PD Dr. med. Michael Grotzer 
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PhD-Student: Fabienne Zurbriggen was working in the project from 1 January – 31 July 2006. On 1 
October 2006, Cornelia E. Rebholz started as a PhD student. 
Duration: The study began on 1st January 2006 and will be funded for 3 years. 
Funding Office: Oncosuisse (265 900 CHF) 
Abstracts:
Rebholz, C.E., Michel, G., von der Weid, N., & Kuehni, C.E (January, 2007). The Swiss Childhood 
Cancer Survivor Study : an update. Annual meeting of the Swiss Paediatric Oncology Group (SPOG), 
Locarno, CH 
Zurbriggen, F., von der Weid, N., Michel, G. & Kuehni, C.E (February, 2006). Late effects in childhood 
cancer survivors: Aims and methods of the new study. Annual meeting of the Swiss Paediatric 
Oncology Group (SPOG), Locarno, CH. 
4.2.2 Health related quality of life and health behaviour in childhood cancer survivors  
This study is an add-on project to the late effects study funded by Oncosuisse, and is funded by the 
Wyeth foundation. 
Aims: 1) To determine in long-term survivors of childhood cancer in Switzerland: a) health related 
quality of life (HRQoL), and the prevalence of risk behaviours (smoking, alcohol), information about 
physical activity, diet and body weight, and b) to compare these findings to existing data from general 
population samples in Switzerland. 
2) To study associations between current HRQoL and health behaviour in survivors with prospectively 
collected data on risk factors, including socio-demographic and clinical determinants at the time of 
diagnosis, treatment modalities and relapses. This will allow us to define groups of children at 
increased risk for detrimental effects and behaviours, who might profit from specific interventions. 
For an update on the project status see 4.2.1. 
Collaborators: The research proposal is a collaborative project of the ISPM Bern (Dr. Claudia Kuehni, 
Main Investigator, Dr. Gisela Michel, Prof. Dr. Matthias Egger, Co-applicants) and of the SPOG (PD 
Dr. Nicolas von der Weid, Co-applicant). 
PhD-Student: Fabienne Zurbriggen was working in the project from 1 January – 31 July 2006. On 1 
October 2006, Cornelia E. Rebholz started as a PhD student. 
Duration: The study began on 1 January 2006 and is funded for 1.5 years. 
Funding Office: Wyeth Foundation (30 088 CHF) 
4.2.3 Completeness of cancer registration and diagnostic accuracy in the Swiss Childhood Cancer 
Registry: validation against independent sources of data  
Aims: The research project aims to validate and complete records of the SCCR against independent 
sources of data from cantonal registries of the Association of Swiss Cancer Registries (VSKR). A 
standardised protocol for regular future cross-validation between these databases is being developed. 
Until the end of 2006 the linkage was completed for 8 of the 9 cantonal registries. Detailed analyses 
are being done until end of July 2007. 
Collaborators: Prof. Dr. Matthias Egger (Main Investigator, ISPM), Dr. Claudia Kuehni (Co-Applicant, 
ISPM), Dr. Silvia Ess (Co-applicant VSKR) and PD Dr. med. Nicolas von der Weid (Co-Applicant, 
SPOG). 
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PhD-Student: Martin Adam started as a PhD student in the project on 1 Mai 2006.  
Duration: The study started on 1st Mai 2006 and is funded for 15 months 
Funding Office: Bernische Krebsliga (Cancer League of Bern, 80 000 CHF) 
Abstract:
Michel, G., Adam, M., von der Weid, N., & Kuehni, C.E (January, 2007). Comparing SCCR with 
Cantonal cancer registries: Is our database complete? Annual meeting of the Swiss Paediatric 
Oncology Group (SPOG), Locarno, CH 
4.2.4 Cefalo: An international case-control study on brain tumours in children and adolescents 
Aims: The main goal of the study is to investigate whether the use of mobile telephones increases the 
risk of developing brain tumours for children or adolescents. In addition, the study will provide a 
comprehensive dataset to investigate other potential risk factors for childhood brain tumour. The 
questions under study will be investigated by means of a case-control study in Denmark, Norway, 
Sweden and Switzerland.  
Study progress: Until the end of 2006, 68 eligible families were invited to participate in the study in 
Switzerland. A total of 43 interviews were completed (including 22 cases). Six families refused to 
participate (3 cases, 3 controls), 2 families agreed to fill in a written questionnaire only, and 17 families 
have not responded yet.  
Collaborators: Dr. Martin Röösli (Head of the Environmental Health Research Group, ISPM Bern), Dr. 
Claudia E Kuehni (Head of the Swiss Childhood Cancer Registry), PD Dr. Michael Grotzer (Head of 
Paediatric Neuro-Oncology, Zurich), PD Dr. Nicolas von der Weid (Head of the Swiss Paediatric 
Oncology Group), Dr. Joachim Schüz (Head of department, Institute of Cancer Epidemiology, 
Copenhagen, Denmark), Dr. Maria Feychting (Professor, Karolinska Institute, Stockholm, Sweden) 
and Dr. Tore Tynes (Cancer Registry of Norway, Oslo, Norway) 
Research assistant: Daniela Jenni started in the project on 1 January 2006.  
Duration: The study started on 1 January 2006 and will be funded for 3 years 
Funding Office: Forschungsstiftung Mobilfunk Schweiz (310 000 CHF), Bundesamt für Gesundheit 
(149 600 CHF) 
Abstract: 
Röösli M., for the Cefalo Study Group. An international case-control study on mobile phone use and 
the risk of brain tumours in children and adolescents (Cefalo study): study design and first experiences 
from the field work. Scientific Workshop hosted by the FGF: Do Children Represent a Special 
Sensitive Group for EMF-Exposure? - State of Research. Stuttgart, 27-29 November 2006. 
(www.cost281.org) 
Schüz J, Feychting, M., Röösli M., Tynes T., Samsø Schmidt L., Johansen C., Prohazka M., Sverin E., 
Jenni D., Kuehni C., Klaboe L. An international case-control study on mobile phone use and the risk of 
brain tumours in children and adolescents (Cefalo study): a report from the field work and first results 
on mobile phone usage among children. 8th International Congress of the European 
Bioelectromagnetics Association (EBEA), Bordeaux 10-13 April 2007. 
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4.2.5 Childhood leukaemia and lymphoma: are incidence and survival in Switzerland associated with 
socioeconomic status? 
Inequalities in health between socio-economic groups are a major public health concern. Numerous 
epidemiological studies have found higher rates of total mortality and morbidity among infants, 
children and adults with a lower socio-economic status (SES), defined on an individual or area-level. 
For childhood cancer, and its most common diagnostic group, childhood leukaemia, the available data 
are contradictory. Some publications suggested that acute lymphoblastic leukaemia was more 
common in children of high SES. However, more recent studies reported associations in the opposite 
direction. Infections have been implicated in the aetiology of lymphomas, which could, in turn, be 
reflected in SES differentials in lymphoma risk. The Swiss setting provides an ideal opportunity to 
study these questions. 
Aims: The research project aims to investigate the association of socio-economic status with the risk 
of developing childhood leukaemia or childhood lymphoma, and to explore whether the association is 
varying with the operational definition of socio-economic status. In addition, we aim to investigate the 
association of socio-economic status with the five-year survival rate for cases of childhood leukaemia 
or childhood lymphoma. 
Collaborators: Dr. Marcel Zwahlen (Main Investigator, ISPM), Prof. Dr. Matthias Egger and Dr. Claudia 
Kuehni (Co-Applicants, ISPM), and PD Dr. med. Nicolas von der Weid (Co-Applicant, SPOG). 
PhD-Student: Martin Adam is managing the project as PhD student.  
Duration: The study started on 1 January 2007 and is funded for 2 years. 
Funding Office: Oncosuisse (171 400 CHF) 
4.2.6 Validating date and cause of death information in the Swiss Childhood Cancer Registry against 
death certificate information from the Swiss Federal Office of Statistics  
Aims: To validate SFSO death certificate information and to update information on vital status in the 
SCCR using an independent information source. 
Method: The Swiss Childhood Cancer Registry (SCCR) patients were linked to information from 
official death certificates recorded by the SFSO using probabilistic record linkage procedures. 
Results: The project validating mortality in the SCCR and mortality statistics of the SFSO showed that 
procedures for probabilistic record linkage could be used to link the SCCR and SFSO datasets and 
that for a major part (80%) of patients recorded as having died in the SCCR a perfectly linked record 
from the SFSO could be found. 
Comparison of the cause of death of the linked records in both databases showed that for the large 
majority of individuals, the cause of death was similar in both datasets. Ninety-three percent of records 
coded according to ICD-8 and 85% of records coded according to ICD-10 (by the SFSO) had either 
both recorded cancer or both recorded something other than cancer as cause of death. The 
agreement between the diagnoses of cancer in the SCCR and the cause of death in the SFSO was 
particularly high for leukaemia. 
Comparison of the agreement between the cause of death in both databases showed that the 
strongest predictor was the coding system used by the SFSO, with the period since 1995 (ICD-10) 
showing poorer agreement compared to the period before, when diagnoses were coded according to 
ICD-8. In addition to changing the classification system, the coding procedures at the SFSO were also 
changed between these two periods, from internal SFSO prioritising rules (for ICD-8) to the prioritising 
rules published by the WHO (for ICD-10). These changes may be related to the deterioration of the 
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agreement between the causes of deaths recorded in the SCCR and the SFSO. Within those two time 
periods, there was no significant change of agreement by calendar years.  
Collaborators: Dr. Claudia Kuehni (Main Investigator, ISPM), Dr. Marcel Zwahlen, Prof. Dr. Matthias 
Egger (Co-Applicants, ISPM), and PD Dr. med. Nicolas von der Weid (Co-Applicant, SPOG). The 
linkage was done by Malcolm Sturdy, the analysis and writing up by Gisela Michel, Marie-Pierre 
Strippoli and Claudia Kuehni. 
Duration: The study was finished at the end of 2005.  
Funding Office: Swiss Federal Statistical Office (SFSO, 20 000 CHF) 
Publications/Reports:
Michel G, Sturdy M, Zwahlen M, Strippoli M-PF, von der Weid N, Kuehni CE. Validating date and 
cause of death information in the Swiss Childhood Cancer Registry against death certificate 
information from the Swiss Federal Office of Statistics (1976-2004). Bern: Institute of Social and 
Preventive Medicine, University of Bern, 2006. 
Michel, G., Zwahlen, M & Kuehni, C. Linkage of mortality data for the Swiss childhood cancer registry 
and the Swiss mortality statistics, in preparation. 
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5 Review of activities 2005/2006 
5.1 Reports and Publications 
The Swiss Childhood Cancer Registry submitted three papers to scientific Journals in 2006: 
• Michel G, von der Weid NX, Zwahlen M, Redmond S, Strippoli MP, Kuehni CE. Incidence of 
childhood cancer in Switzerland: The Swiss childhood cancer registry. Pediatric Blood & 
Cancer 2007;DOI 10.1002/pbc.21129. 
• Roosli M, Michel G, Kuehni CE, Spoerry A. Cellular telephone use and time trends in brain 
tumour mortality in Switzerland from 1969 to 2002. European Journal of Cancer Prevention 
2007;16(1):77-82. 
• Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni C. The Swiss 
Childhood Cancer Registry: rationale, organisation and results for the years 2001-2005. under 
review 
The linkage of the SCCR data with the mortality statistics of the Swiss Federal Statistical Office 
(SFSO) was repeated including the year 2004. A report is available from the SCCR: 
• Michel G, Sturdy M, Zwahlen M, Strippoli M-PF, von der Weid N, Kuehni CE. Validating date 
and cause of death information in the Swiss Childhood Cancer Registry against death 
certificate information from the Swiss Federal Office of Statistics (1976-2004). Bern: Institute 
of Social and Preventive Medicine, University of Bern, 2006. 
5.2 Concept for the planned database renewal 
The current SCCR database was implemented in 1992 using the Microsoft Access 2.0 relational 
database system running on a self-contained Windows desktop PC. New requirements on the SCCR 
database, mainly in the areas of data security / privacy and data model, provided the opportunity to 
analyse the current situation, develop a replacement SCCR database concept and implement the 
result. 
The new database concept includes various improvements: 
• Strict separation of personal data from all other disease relevant information 
• Keeping history of data changes (such as changes of address, names etc.) 
• SQL database server 
• ACCESS front end 
In 2005 and 2006 the data have been migrated from the old database to the new data structure. The 
database is currently under construction and will be finalised by June 2007. A detailed description will 
be included in the next Annual Report. 
24 
5.3 Funding of the SCCR 
The SCCR thanks the following sponsors for their generous unrestricted financial support: 
 
Since 2004  
Swiss Paediatric Oncology Group 
2006-2008  
Novartis 
Winterthur 
2007  
GlaxoSmithKline 
Kinderkrebshilfe Schweiz 
Amgen 
Stiftung zur Förderung von sozialen Massnahmen 
in der Kranken- und Unfallversicherung 
2006  
Bristol-Myers Squibb 
Interpharma 
Baxter 
2005  
Valiant Bank 
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5.4 General registry work 
5.4.1 Recoding of Diagnoses 
Until 2004, all tumours were coded according to the coding used by the American Paediatric Oncology 
Group (POG). In 2005 and 2006 all tumours registered in the SCCR have been retrospectively coded 
according to: 
• The third revision of the International Classification of Childhood Cancer (ICCC-3)5
• The third edition of the International Classification of Diseases for Oncology (ICD-O-3)6
• The tenth revision of the International Statistical Classification of Diseases and Related Health 
Problems (ICD-10)7.
All tumours were separately coded by two independent coders and double checked with logical 
analyses and automated coding systems from the German Childhood Cancer Registry. 
5.4.2 Adaptations of the current database 
The following fields have been added to the current database: 
• Information about consent given by the patient or his/her parents to the data transfer from the 
clinic to the SCCR 
• Information about patient registration: person entering the first notification into the database 
and date of entry. 
• Validation of patient address: date when the patient address was validated; if information 
concerns patient or parent; result of the validation 
• Details about the therapy protocol: exact study name, study group (e.g. COG, GPOH, SIOP), 
abbreviated study name, year when study was initiated, treatment regimen, modifications to 
the study protocol, information if patient was entered as a study patient or only treated 
according to a certain protocol but not entered into the study, comments 
The following additional information from new sources has been added to the database and old 
information has been updated. 
• Date of death was added for several patients after detailed review of information from the 
mortality statistics of the SFSO, local databases from the paediatric oncology clinics, and 
information from the cytogenetics database. 
• Personal information (current address) has been updated in the course of the late outcomes in 
childhood cancer survivors research project. Each clinic was visited and details of patients 
were updated from the patient charts. 
5.4.3 Improvement of the information form 
Until recently information about new childhood cancer patients in each of the 9 paediatric oncology 
clinics had been sent to the SCCR on paper forms, which were entered into the electronic database 
 
5 Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer 
2005;103(7):1457-67. 
6 World Health Organization. International Statistical Classification of Diseases for Oncology - 3rd Edition (ICD-O-3). Geneva: 
World Health Organization; 2000. 
7 World Health Organization. International statistical classification of diseases and related health problems - Tenth Revision. 
Geneva: World Health Organization; 1993. 
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and finally archived at the SPOG secretariat. To improve the quality of the information and enable 
electronic entry an interim form was developed on MS Excel. This form is used until the final data 
transmission form is available together with the new database. 
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6 Publications 
We only report publications from 2005- 2007 closely related to the SCCR or publications with at least 
two authors from the SPOG. Additional publications related to the SPOG and the SCCR can be found 
on the SCCR-website: www.kinderkrebsregister.ch. 
6.1 Peer reviewed publications 
2007  
Michel G, von der Weid NX, Zwahlen M, Redmond S, Strippoli MP, Kuehni CE. Incidence of childhood 
cancer in Switzerland: The Swiss childhood cancer registry. Pediatric Blood & Cancer, DOI 
10.1002/pbc.21129. 
Röösli M, Michel G, Kuehni CE & Spoerry A. Cellular telephone use and time trends in brain tumour 
mortality in Switzerland from 1969 to 2002. European Journal of Cancer Prevention. 2007 
16(1):77-82.
2006  
Kuehni CE, Zwahlen M. Commentary Commentary: Numerous, heterogeneous and often poor – the 
studies on childhood leukaemia and socioeconomic status. Int J Epidemiol 2006;35:384-5. 
Brown AE, Leibundgut K, Niggli FK, Betts DR. Cytogenetics of pineoblastoma: four new cases and a 
literature review. Cancer Genet Cytogenet 2006;170:175-179.  
Reid AG, Seppa L, von der Weid N, Niggli FK, Betts DR. A t(12;17)(p13;q12) identifies a distinct TEL 
rearrangement-negative subtype of precursor-B acute lymphoblastic leukemia. Cancer Genet 
Cytogenet 2006;165:64-69. 
Schlapbach LJ, Aebi C, Otth M, Luethy AR, Leibundgut K, Hirt A, Ammann RA. Serum levels of 
mannose-binding lectin and the risk of fever in neutropenic pediatric cancer patients. Pediatr 
Blood Cancer, Dez 1, 2006 
Wallach, M., Balmer, A., Munier, F., Houghton, S., Pampallona, S., von der Weid, N., et al. (2006). 
Shorter time to diagnosis and improved stage at presentation in Swiss patients with 
retinoblastoma treated from 1963 to 2004. Pediatrics, 118(5), e1493-1498. 
doi:10.1542/peds.2006-0784 
Zucol F, Ammann RA, Berger C, Aebi C, Altwegg M, Niggli FK, Nadal D. Real-time quantitative broad-
range PCR assay for detection of the 16S rRNA gene followed by sequencing for species 
identification. J Clin Microbiol 2006;44:2750-2759.  
2005 
Betts DR, Avoledo P, von der Weid N, Greiner J, Niggli FK. Cytogenetic characterization of Ewing 
tumors with high-ploidy. Cancer Genet Cytogenet 2005;159:160-163.  
Betts DR, Cohen N, Leibundgut KE, Kuhne T, Caflisch U, Greiner J, Traktenbrot L, Niggli FK. 
Characterization of karyotypic events and evolution in neuroblastoma. Pediatr Blood Cancer. 
2005 Feb;44(2):147-57.  
6.2 Other Papers 
2007 
Diezi M, Tercier S, Osterheld M-C, Joseph J-M, Tumeurs rénales de l’enfant. Revue Médicale Suisse 
2007;3:360-5 
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2006 
Ammann RA. The SPOG 2003 FN Study on Children with Cancer and Fever in Neutropenia: Risk 
Assessment and Low-Risk-Adapted Therapy. Schweizer Krebsbulletin 26:278-280, 2006 
Beck Popovic M, Joseph JM, Gross N. Neuroblastoma. Rev Med Suisse. 12;2:999-1004, 2006 
Vajtai I, Kappeler A, Lukes A, Arnold M, Ridolfi Lüthy A, Leibundgut K. Papillary glioneuronal tumor. 
Pathol Res Pract 202:107-112, 2006 
Von der Weid N, Beck Popovic M. Acute lymphoblastic leukemia in children and adolescents. Rev 
Med Suisse 2:873-876, 2006 
Wagner HP, von der Weid NX. La maladie die Hodgkin de l’enfant: Un maximum de survie avec un 
minimum de séquelles. Rev Med Suisse 2:2812-2815, 2006 
2005 
von der Weid N.  Spätfolgen nach Krebserkrankung und deren Therapie. Pädiatrie 2005;3:20-22,  
Nobile L, Heinkel J. Bernasconi G , Rossetti G. Pulmonary Inflammatory Pseudotumor in a toddler. 
Krebsbulletin, June 2005: 140-143. 
von der Weid N. Spécificités du cancer de l'enfant et de l'adolescent. Revue med suisse 2005. 
von der Weid N, Beck Popovic M. Leucémie lymphoblastique aiguë de l'enfant et de l'adolescent. 
Revue med suisse 2005 
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7 Abbreviations 
 
ACCIS  Automated Childhood Cancer Information System 
COG Children’s Oncology Group, formerly Pediatric Oncology Group 
GCCR German Childhood Cancer Registry 
GPOH Gesellschaft für Pädiatrische Onkologie und Hämatologie 
IACR International Association of Cancer Registries 
IARC International Association of Research in Cancer 
ICCC-3 International Classification of Childhood Cancer, Third revision 
ICD-10 International Classification of Diseases, Tenth revision 
ICD-O-3 International Classification of Diseases in Oncology, Third revision 
ISPM Institute of Social and Preventive Medicine, Bern 
LCH Langerhans cell histiocytosis 
NRCT National Registry of Childhood Tumours, Oxford, England 
POG Pediatric Oncology Group 
SCCR Swiss Childhood Cancer Registry 
SES Socio-economic status 
SFSO Swiss Federal Statistical Office 
SPOG Swiss Paediatric Oncology Group 
VSKR /ASRT Association of Swiss Cancer Registries 
WHO World Health Organisation 
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8 Appendix 
8.1 Appendix 1: Classification of childhood cancer used by the SCCR 
8.1.1  ICCC-3 
The third edition of the International Classification of Childhood Cancer (ICCC-3) represents the 
standard for presentation of international data on childhood cancer incidence and survival8. It applies 
the rules, nomenclature and codes (morphology, topography and behaviour) of the ICD-O-3. 
Furthermore, ICCC-3 categories are defined in conformity with international classifications of the 
pathology and genetics of childhood cancers. In the ICCC-3, three hierarchical levels have been 
developed: level one consists of 12 main diagnostic groups and level two of 47 diagnostic subgroups. 
These two levels of the ICCC-3 allow standardised comparison of the broad categories of childhood 
tumours. Level three, an optional “extended” classification, comprises two to eleven divisions of 
selected diagnostic subgroups. The division of some diagnostic subgroups, e.g. leukaemias and Non-
Hodgkin lymphomas, reflects the availability of detailed cytogenetic or molecular information that 
permits homogeneous groups of tumours to be distinguished within them and thus allows their 
separate study. Most childhood cancer registries only use level one and two. Only malignant 
neoplasms are classified in ICCC-3, with the exception of non-malignant intracranial and intraspinal 
tumours. Tumours known to occur only rarely in young patients are also included in ICCC-3. The 
ICCC-3 is used if data are compared with other childhood cancer registries. 
8.1.2 ICD-O-3 
The third edition of the International Classification of Diseases for Oncology (ICD-O-3) 9 has been 
developed by a working group hosted by IARC/WHO. The morphology code for neoplasm has been 
revised, especially for lymphomas and leukaemias. In contrast to the ICD-10 classification, ICD-O-3 
uses only one set of four characters for topography (based on the malignant neoplasm section of ICD-
10). The topography code remains the same for all neoplasms of that site. The behaviour code is 
incorporated as the fifth digit in the morphology field. It identifies whether the tumour is malignant, 
benign, of uncertain or unknown behaviour, in situ, presumed to be primary or secondary. ICD-O-3 is 
used to compare data with general cancer registries. 
8.1.3 ICD-10 
The International Statistical Classification of Diseases and Related Health Problems (ICD)10 permits 
the systematic recording, analysis, interpretation and comparison of mortality and morbidity data 
collected in different regions and at different time periods. The ICD has become the international 
standard diagnostic classification for all general epidemiological purposes. The ICD-10 classification 
comprises three volumes: Volume 1 contains the main classifications; Volume 2 provides guidance for 
users of the ICD; and Volume 3 is the alphabetical index to the classification. Classification is divided 
into 21 chapters. The first character of the ICD code is a letter. Each letter is associated with a 
particular chapter, e.g. the letter D is used in both chapter II “Neoplasms” and chapter III “Diseases of 
the blood and blood-forming organs and certain disorders involving the immune mechanism”. The 
topography code in Volume 3 describes the site and the behaviour of the neoplasm: malignant, 
 
8 Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer 
2005;103(7):1457-67. 
9 World Health Organization. International Statistical Classification of Diseases for Oncology - 3rd Edition (ICD-O-3). Geneva: 
World Health Organization; 2000. 
10 World Health Organization. International statistical classification of diseases and related health problems - Tenth Revision. 
Geneva: World Health Organization; 1993. 
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secondary or metastatic, in situ benign, or unknown behaviour. The morphology codes listed in 
Volume 1 are the same as those used in the special adaptation of the ICD for oncology, the ICD-O-2. 
 
